---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-022188"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2024-07-03T23:59:59+00:00"
generated_at: "2026-05-31T23:29:13.533382+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pieris Pharmaceuticals' Servier collaboration terminated; S095012 Phase 1 halted on safety concern

## Summary
- Servier terminated license/collaboration agreement effective Dec 27, 2024, citing a potential safety concern in the S095012 Phase 1 study.
- Pieris will discontinue all development of S095012; no further pursuit of the asset.
- Non-exclusive Anticalin platform license also terminates with the collaboration agreement.
- Pieris remains eligible for milestones from Boston Pharma and Pfizer partnerships on other 4-1BB bispecific assets: up to $200M development and >$415M commercial milestones.

## SEC filing metadata
- accession: 0001437749-24-022188
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2024-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774924022188/0001437749-24-022188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774924022188/pirs20240612_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-022188
- JSON: https://secwatch.observer/filing/0001437749-24-022188.json
- Plain text: https://secwatch.observer/filing/0001437749-24-022188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.